Ascletis تعلن عن بيانات ما قبل سريرية إيجابية لأشمل خط إنتاج ببتيدي فموي يُعطى مرة واحدة أسبوعياً لعلاج السمنة

Ascletis has released encouraging preclinical trial results highlighting its innovative once-weekly oral peptide pipeline designed to treat obesity and related metabolic conditions. The company's therapeutic portfolio successfully addresses all four clinically validated targets within the obesity sector, establishing a competitive advantage in drug delivery mechanisms. By aiming for first-in-class fixed-dose combinations, Ascletis seeks to offer patients more convenient and efficacious alternatives to existing injectable treatments. The obesity drug market remains one of the most lucrative and rapidly expanding segments within the global pharmaceutical industry. Further clinical development milestones will be closely monitored by industry analysts and investors tracking metabolic therapeutics.